Nervonik announced that it closed a $13 million Series A funding round to support its opioid-free peripheral nerve stimulation (PNS) system. U.S. Venture Partners (USVP) led the round for the Los Angeles-based company. Foothill Ventures, Correlation Ventures and other investors participated, too. The funding follows earlier SAFE and convertible note financings worth $4.4 million. Nervonik […]
Pain Management
Onward reports positive spinal cord stim results for ARC-EX
Onward Medical today announced positive study results from an evaluation of its ARC-EX spinal cord stimulation therapy system. Results from the investigator-sponsored Pathfinder 2 study, published in Neuromodulation: Technology at Neural Interface, detailed findings from one year of evaluations for people utilizing ARC-EX therapy. It showed that ARC-EX, combined with activity-based rehabilitation, delivered functional improvements […]
Salvia BioElectronics reports first migraine therapy implant in The Netherlands
Salvia BioElectronics has reported the first patient implanted with its ultra-thin implant for chronic migraine in The Netherlands. The first implant in the country took place at Erasmus MC in Rotterdam as part of a clinical study. Investigators are currently evaluating the technology in an ongoing study in Belgium, Australia and now The Netherlands, where […]
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO). Audobon, Pennsylvania-based Globus agreed to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, it plans to pay $5.85 per share, with the deal’s total equity value reaching approximately $250 million. Redwood City, […]
Medtronic data highlights benefits of closed-loop spinal cord stim
Medtronic today announced 12-month data demonstrating the benefits of its Inceptiv closed-loop spinal cord stimulator (CL-SCS). The clinical trial evaluated Inceptiv in patients with chronic low-back pain (CLBP) and leg pain. Medtronic plans to present data at the North American Neuromodulation Society (NANS) 2025 meeting next week in Orlando. Inceptiv treats chronic pain and represents […]
FDA clears Nalu peripheral nerve stim tech for whole-body MRI
Nalu Medical announced today that the FDA cleared expanded labeling of its peripheral nerve system to include whole-body MRI use. The clearance gives physicians greater flexibility in treating chronic pain, minimizing MRI-related limitations with whole-body MRI-conditional use. Nalu’s system now enables personalized care without compromising future diagnostic imaging needs. Carlsbad, California–based Nalu offers FDA-cleared spinal […]
Nevro still looking at strategic options, Q4 revenue prelims beat Street
Nevro (NYSE:NVRO) today reported preliminary fourth-quarter revenue numbers were down year-over-year but were better than Wall Street analyst expectations. The developer of implantable spinal cord stimulation (SCS) tech also said that it remains in ongoing discussions as it continues to explore strategic options to accelerate its growth, diversify its product portfolio and deliver shareholder value. […]
Saluda Medical raises $100M for closed-loop neuromod
Saluda Medical announced today that it closed a $100 million financing to support its novel closed-loop, dose-control neuromodulation platform. Existing investor Redmile Group led the financing round. Other existing investors Wellington Management, TPG Life Sciences Innovation, Fidelity Management & Research Company, Action Potential Venture Capital and funds and accounts advised by T. Rowe Price Associates […]
Electrocore to acquire NeuroMetrix and its Quell neuromod tech
ElectroCore (Nasdaq:ECOR) announced that it agreed to acquire NeuroMetrix (Nasdaq:NURO) and its Quell neuromodulation platform. NeuroMetrix develops the Quell platform, a wearable, app- and cloud-enabled neuromodulation platform. It treats fibromyalgia symptoms and lower-extremity chronic pain. The company also offers DPNCheck, a point-of-care screening test for peripheral neuropathy. However, ElectroCore said it expects NeuroMetrix to divest […]
SetPoint Medical submits neuromod device to FDA
SetPoint Medical announced today that it filed with the FDA for premarket approval (PMA) of its neuroimmune modulation device. The Valencia, California-based company develops the system as a potential first-of-its-kind treatment for moderate-to-severe rheumatoid arthritis (RA). Its target population are incomplete responders or are intolerant to biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). SetPoint designed […]
ShiraTronics initiates FDA IDE study for implantable neuromod
ShiraTronics announced that it initiated its FDA investigational device exemption (IDE) pivotal trial for its neuromodulation therapy. The RELIEV-CM2 clinical study evaluates the company’s neuromodulation therapy for chronic migraine. Investigators completed the first implants in the U.S. and Australia, kicking off the evaluation of the system’s long-term safety and efficacy. In October, the company raised […]
